ClinicalTrials.gg
CompletedNCT02125227Updated Oct 9, 2014

Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers

A Phase 1 interventional study of Rosuvastatin, Metformin, YH14755 and YH14755 in Healthy, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-09.

Sponsored by Yuhan Corporation · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the Effect of Food on the Pharmacokinetics of YH14755 in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female with a (BMI) between 18.5 and 25 kg/m2
  2. Who has not suffered from disease
  3. Provision of signed written

Exclusion criteria

Exclusion Criteria:

  1. History of and disease
  2. A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs.
  3. Administration of other products within 3 months prior to the first dosing.
  4. Administration of herbal medicine within 4 weeks or administration of ethical drugs within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
  5. Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Group 1 of Study A

    single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755

    Drug: Rosuvastatin, Metformin, YH14755

  • Experimental
    Group 2 of Study A

    single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin

    Drug: Rosuvastatin, Metformin, YH14755

  • Experimental
    Group 1 of Study B

    single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast

    Drug: YH14755

  • Experimental
    Group 2 of Study B

    single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state

    Drug: YH14755

Interventions

  • DrugRosuvastatin, Metformin, YH14755

    Drug pages: Rosuvastatin · Metformin

    single dose

    Also known as: Crestor, GlucodaunOR, YH14755

  • DrugYH14755

    single dose

06

What researchers measure

Primary outcomes

  1. AUClast of rosuvastatin and metformin

    Time frame: 0~48hr, totally 17 points

  2. Cmax of rosuvastatin and metformin

    Time frame: 0~48hr, totally 17 points

Secondary outcomes

  1. Tmax of rosuvastatin and metformin

    Time frame: 0~48hr, totally 17 points

  2. t1/2 of rosuvastatin and metformin

    Time frame: 0~48hr, totally 17 points

  3. %AUC of rosuvastatin and metformin

    Time frame: 0~48hr, totally 17 points

  4. AUCinf of rosuvastatin and metformin

    Time frame: 0~48hr, totally 17 points

07

Study locations

1 site
  • Chonbuk National University Hospital
    Jeonju-si, Jeollabuk-do 561712, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2014
First posted
Apr 29, 2014
Start
Apr 2014
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Last update
Oct 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02125227
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Apr 29, 2014
Start date
Apr 2014
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Oct 9, 2014

Study contacts

Mingul Kim, MD, Ph.D
principal investigator · Chonbuk National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Metformin

Start the discussion